For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
GHRP-2 (pralmorelin) is a synthetic hexapeptide GHS-R1a agonist and the most potent traditional GH-releasing peptide. It is the only GH secretagogue with regulatory approval anywhere in the world -- approved in Japan since 2004 as a diagnostic agent for GH deficiency. Unlike the more selective ipamorelin, GHRP-2 also elevates cortisol and prolactin at therapeutic doses, a distinguishing pharmacological liability. A negative 48-week intranasal growth trial in 126 GH-deficient children found no benefit on height SD score.
GHRP-2 has a more complex human evidence picture than its reputation in the research community suggests. The most widely cited finding -- that it is the most potent traditional GH secretagogue -- is well-supported by controlled human studies. The least discussed finding -- a 48-week, 126-patient, double-blind trial in GH-deficient children showing no growth benefit from intranasal GHRP-2 -- receives almost no attention in community content. That negative trial matters.
The Japanese regulatory approval (pralmorelin, GHRP Kaken 100) is genuine but narrowly scoped: it is a diagnostic provocative test, not a treatment. A single intravenous bolus is used to distinguish GH-sufficient from GH-deficient individuals based on peak GH response. The approval does not validate chronic therapeutic use, body composition benefits, anti-aging applications, or any of the common off-label uses in the research community.
The FDA Category 2 status (as of 2026) reflects regulatory concern about the cortisol and prolactin elevation that distinguishes GHRP-2 from more selective compounds like ipamorelin. Multiple analysts covering the 2026 FDA reclassification have specifically cited GHRP-2 and GHRP-6 as compounds likely to remain on Category 2 even as 14 other peptides return to Category 1. WADA names pralmorelin explicitly on its S2.2 list. Athletes subject to doping control face a positive test from any use.
GHRP-2 was originally developed in the early 1990s by C.Y. Bowers at Tulane University and Polygen in Germany as part of a systematic program to create synthetic GH secretagogues. The compound was subsequently licensed to Kaken Pharmaceutical in Japan, which conducted the clinical development program leading to regulatory approval. The INN (International Nonproprietary Name) is pralmorelin.
GHRP-2 belongs to the first generation of synthetic GH-releasing peptides, a class discovered in the 1980s when Bowers found that small enkephalin-derived peptides could potently stimulate GH release through a receptor distinct from the GHRH receptor. GHRP-2 is a second-generation optimization of the original GHRP-6 scaffold: substituting D-2-naphthylalanine for D-tryptophan at position 2 of the hexapeptide sequence confers enhanced binding affinity and GH-releasing potency at the GHS-R1a receptor. The endogenous ligand for this receptor, ghrelin, was not identified until 1999 -- several years after GHRP-2's characterization -- making GHRP-2 a pharmacological orphan whose receptor was found after the drug.
Kaken Pharmaceutical received approval from the Japanese Ministry of Health, Labour and Welfare in 2004 for pralmorelin (GHRP Kaken 100) as a diagnostic stimulation test for GH deficiency in adults and children over age 4. The compound is administered as a single 100 mcg IV bolus, and peak GH response is measured. This made pralmorelin the first GH secretagogue approved for clinical use anywhere in the world, a distinction it retains. The diagnostic application exploits GHRP-2's potent, reliable GH-releasing effect as a provocative test rather than as ongoing treatment.
GHRP-2 is a potent agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor activated by the endogenous gut peptide ghrelin. GHS-R1a is expressed in the anterior pituitary somatotrophs and in the hypothalamic arcuate nucleus. GHRP-2 acts at both sites: at the pituitary, it directly stimulates GH release from somatotrophs; at the hypothalamus, it stimulates GHRH release and inhibits somatostatin release. The net effect is a large, rapidly peaking GH pulse that exceeds the GH response to maximal-dose GHRH alone.
The dual mechanism -- pituitary and hypothalamic -- explains why GHRP-2 and GHRH are synergistic when administered together. GHRH increases the amplitude of GH release per somatotroph cell, while GHRP-2 increases the number of somatotrophs recruited into the GH pulse and suppresses somatostatin tone. Combined administration produces GH responses two to three times greater than either agent alone, a pharmacological basis for the common CJC-1295 plus GHRP-2 stack in the research community.
Unlike the more selective ipamorelin, GHRP-2 also stimulates ACTH and cortisol release through hypothalamic corticotropin-releasing hormone (CRH) activation, and prolactin release through a separate mechanism. Arvat et al. (1997) established that the ACTH/cortisol response to GHRP-2 is comparable in magnitude to that of hCRH itself. This is a meaningful neuroendocrine perturbation, not a trivial side effect. The cortisol elevation is dose-dependent but occurs across the range used therapeutically.
Appetite stimulation through GHS-R1a activation in the hypothalamus is a third mechanism, engaging neuropeptide Y (NPY) and agouti-related peptide (AgRP) pathways -- the same hunger-signaling circuits activated by endogenous ghrelin. This produces moderate appetite stimulation in humans, less pronounced than GHRP-6 but more than ipamorelin.
The Japanese multicenter trial established pralmorelin (GHRP-2) as a reliable GH provocative test. A single IV 100 mcg bolus produces a peak GH response that distinguishes GH-sufficient from GH-deficient individuals with clinically useful accuracy. Cutoff values are peak GH greater than 16 ng/mL in children and greater than 9 ng/mL in adults for GH-sufficient classification. The test is considered easier to perform than the insulin tolerance test (ITT, the traditional gold standard) because it does not require hypoglycemia induction, which carries syncope and seizure risk, particularly in children.
A 2022 study in 36 patients with suspected hypopituitarism demonstrated an additional diagnostic utility: the ACTH response to GHRP-2 can screen for secondary adrenal insufficiency. An ACTH response of less than 1.55-fold above baseline showed 83% sensitivity and 88% specificity for pituitary adrenal insufficiency, and the combination of ACTH response and peak cortisol achieved 100% specificity with 94% accuracy. The authors recommended measuring ACTH alongside GH in the GHRP2 test to avoid missing concomitant adrenal insufficiency, which was present in 47% of severe GHD patients in this cohort.
This diagnostic application represents the only evidence-backed, regulatory-approved use of GHRP-2 in humans. All therapeutic applications (body composition, anti-aging, muscle recovery) are off-label extrapolations from GH secretagogue pharmacology.
The diagnostic application is the strongest GHRP-2 evidence by regulatory and methodological standards. The Japanese approval is genuine and based on a well-designed multicenter trial. The added utility for adrenal insufficiency screening is a 2022 finding that adds clinical value. None of this validates chronic therapeutic use: a diagnostic bolus test is pharmacologically very different from daily subcutaneous dosing for weeks to months.
Arvat et al. (1997) is the definitive pharmacological comparison establishing GHRP-2's GH-releasing potency. At 1 mcg/kg IV, GHRP-2 and hexarelin produced GH responses exceeding those of the maximally effective dose of GHRH in healthy young adults (p less than 0.05). At 2 mcg/kg, the GH response was further increased. In elderly subjects, GHRP-2 still produced a substantial GH response, though lower than in young adults. The study also confirmed the hormonal non-selectivity: ACTH and cortisol responses to GHRP-2 were similar to those of hCRH; prolactin responses were modest but present.
Mericq et al. (1998) demonstrated that sustained SC GHRP-2 dosing in GH-deficient children produced dose-dependent increases in overnight episodic GH secretion and higher growth velocity during treatment compared to pre-treatment periods. The combination of GHRP-2 with GHRH in the final 2 months produced further augmentation of GH output, directly demonstrating the synergistic mechanism in a clinical setting. No adverse effects or toxicities were observed during 8 months of treatment.
These two studies form the pharmacological foundation for GHRP-2's therapeutic claims: it is a potent GH-releasing agent that surpasses GHRH alone, combines synergistically with GHRH analogs, and can sustain GH elevation with subcutaneous administration over months without observed toxicity in this small cohort.
The Arvat 1997 and Mericq 1998 studies are well-designed and provide genuine mechanistic and pharmacological evidence for GHRP-2's GH-releasing potency. The Mericq study in 6 children is very small and in a specific population (GH-deficient children), limiting extrapolation to healthy adults using GHRP-2 for body composition. No controlled body composition trial in healthy adults using GHRP-2 has been published.
This is the most important and least-cited human trial of therapeutic GHRP-2 use. In 126 GH-deficient children treated for 48 weeks with intranasal GHRP-2 twice daily, there was no significant difference in height SD score change between placebo, low-dose, and high-dose groups. The changes in mean height SD score were 0.07 SD in the placebo group, 0.03 SD in the low-dose group, and 0.02 SD in the high-dose group -- numerically in the wrong direction, with placebo outperforming both active doses.
The authors noted that despite the intranasal GHRP-2 spray producing measurable GH secretion in preliminary testing (children were required to show a GH response greater than 9 ng/mL after intranasal GHRP-2 to enroll), this GH stimulation did not translate into measurable linear growth benefit over 48 weeks.
This trial is the most rigorous test of GHRP-2 as a therapeutic GH secretagogue in a GH-deficient population. Its failure to show benefit is a meaningful negative result that the research community rarely acknowledges. The route (intranasal vs. SC or IV) may explain part of the failure, but the study does directly challenge the assumption that GHRP-2's GH-releasing activity translates into clinically meaningful therapeutic outcomes.
A 48-week, 126-patient, double-blind, placebo-controlled trial in GH-deficient children finding no benefit on the primary endpoint of height SD score is a significant negative result. It does not definitively rule out therapeutic benefit from SC administration (which was not tested in this trial) or in healthy adults, but it substantially weakens the extrapolation from GH pulse pharmacology to therapeutic outcomes. This trial belongs prominently in any honest evaluation of GHRP-2.
Seven healthy lean males ate 35.9 plus or minus 10.9% more food following GHRP-2 infusion versus saline (136.0 plus or minus 13.0 kJ/kg versus 101.3 plus or minus 10.5 kJ/kg, p = 0.008). Every subject increased food intake under GHRP-2 conditions. Macronutrient composition did not differ between conditions. As expected, serum GH rose significantly during GHRP-2 infusion (AUC 5,550 plus or minus 1,090 mcg/L/240 min versus 412 plus or minus 161 mcg/L/240 min, p = 0.003).
This was the first study to directly demonstrate that GHRP-2 increases food intake in humans through the same GHS-R1a pathway as ghrelin. The 35.9% increase in caloric intake is substantial and consistent across all subjects, suggesting a reliable orexigenic effect.
For users pursuing body composition goals involving caloric restriction or fat loss, this appetite-stimulating effect represents a meaningful practical liability that is not present with ipamorelin. For users seeking to increase muscle mass through caloric surplus, this effect could theoretically be advantageous.
A small but clean crossover study (n=7) demonstrating substantial appetite stimulation -- 35.9% increase in ad libitum food intake. This is a real and relevant pharmacological effect. It is less pronounced than with GHRP-6 but more than with ipamorelin. Users targeting fat loss while using GHRP-2 should account for this appetite stimulation as a practical confound.
Arvat et al. (1997) established the benchmark comparison: GHRP-2's ACTH and cortisol responses are similar in magnitude to those of hCRH (human corticotropin-releasing hormone), the physiological driver of the stress response. This is not a minor or negligible hormonal perturbation. Every dose of GHRP-2 produces an ACTH/cortisol response equivalent to a meaningful stress stimulus.
Prolactin elevation was modest -- lower than TRH (a potent prolactin secretagogue) but present and dose-dependent. Standard research doses of 100 to 200 mcg SC produce prolactin elevations that are generally not clinically significant in short-course use, but the cumulative effect of three-times-daily dosing protocols has not been studied.
The contrast with ipamorelin is pharmacologically important: ipamorelin at GH-releasing doses produces minimal cortisol and prolactin elevation. This difference is why ipamorelin is often described as the more selective, preferable alternative for users who want GH stimulation without HPA axis activation. For users with stress-sensitive conditions, anxiety disorders, sleep disruption, or those seeking to minimize cortisol exposure, GHRP-2's non-selectivity is a genuine liability.
The cortisol and prolactin elevation from GHRP-2 is not a minor side note -- the ACTH/cortisol response benchmarks to hCRH in controlled studies. This is a documented, reproducible pharmacological effect across multiple human studies. It is the primary reason GHRP-2 is expected to remain on FDA Category 2 when more selective alternatives (ipamorelin) are available. Users should weigh this against ipamorelin for most applications.
More potent GH release than GHRP-6. Significant appetite stimulation at doses above 200mcg.
GHRP-2 has more human pharmacokinetic and dosing data than almost any research peptide, primarily from the Japanese diagnostic program and multiple controlled endocrine studies. Standard research community dosing of 100 to 300 mcg SC two to three times daily is empirically derived from the diagnostic dose and small therapeutic studies. The synergistic combination with CJC-1295 or Sermorelin is based on the GHRH/GHRP dual mechanism characterized in human studies. WADA prohibition at all times means any use by tested athletes constitutes a doping violation. FDA Category 2 status means compounding pharmacies in the USA cannot legally prepare GHRP-2 as of 2026. Ipamorelin produces similar GH stimulation with significantly less cortisol and prolactin elevation and is the preferred alternative for most therapeutic research applications.
Within the GH secretagogue class in this database: Ipamorelin (profile #7) is the direct comparison. Both act on GHS-R1a and produce pulsatile GH release. Ipamorelin is more selective (minimal cortisol, ACTH, prolactin elevation; minimal appetite stimulation) and is the preferred choice for most therapeutic research protocols. GHRP-2 is more potent per mcg for GH release and produces stronger appetite stimulation. GHRP-2 is typically paired with CJC-1295 (profile #8) or Sermorelin (profile #18) for synergistic GH effects. MK-677 (profile #27) also acts on GHS-R1a but is oral, longer-acting, and has no WADA/Category 2 issues. Hexarelin (not yet profiled) is pharmacologically similar to GHRP-2 with even stronger cortisol response and pronounced tachyphylaxis.
GHRP-2 has the most characterized human safety profile of any peptide GH secretagogue, by virtue of the Japanese diagnostic approval program and decades of controlled clinical studies. The safety picture is mixed: generally well-tolerated in acute and short-term use, with meaningful endocrine perturbations from chronic use that have not been formally studied.
In the Japanese diagnostic approval setting (single 100 mcg IV bolus), GHRP-2 is well tolerated. No serious adverse events attributable to pralmorelin were reported in the pivotal multicenter trial. The most common acute effects are transient flushing, mild drowsiness, and a sensation of warmth, all typically resolving within 30 to 60 minutes.
The cortisol and prolactin elevation is the primary safety concern for chronic therapeutic use. Arvat et al. (1997) demonstrated that ACTH/cortisol responses to GHRP-2 are comparable to hCRH in magnitude. Chronic cortisol elevation from repeated daily dosing has not been studied in controlled long-term human trials, and the consequences of this effect over months of use are unknown. In theory, sustained HPA axis activation from frequent dosing could contribute to cortisol-related adverse effects including sleep disruption, insulin resistance, and mood changes. This concern is theoretical rather than documented from clinical trial data, but it is mechanistically grounded.
Prolactin elevation is modest at standard research doses (100 to 200 mcg SC) and is typically not clinically significant in short-course use. Chronic elevations could theoretically affect gonadal function in both sexes. Appetite stimulation (35.9% increase in ad libitum food intake in the Laferrere study) is relevant for body composition goals where caloric control is intended. Water retention from GH-mediated IGF-1 elevation is a class effect shared across all GH secretagogues. No cardiovascular adverse events attributable to GHRP-2 have been reported in published human studies.
GHRP-2 holds a unique position in the GH secretagogue class: it is the only member with regulatory approval anywhere in the world, its GH-releasing pharmacology is the most extensively characterized in controlled human studies, and it has a documented therapeutic failure in the only long-term growth trial ever conducted.
The pharmacological case for GHRP-2 is real. It releases more GH than maximal-dose GHRH. It synergizes with GHRH analogs. It is well-characterized in humans with 30+ years of clinical study. The diagnostic approval in Japan is based on genuine multicenter data. The 8-month subcutaneous dosing study in children showed dose-dependent GH increases without toxicity.
The therapeutic case has a large hole in it. The 48-week, 126-patient, double-blind trial in GH-deficient children found no growth benefit from intranasal GHRP-2. A body composition trial in healthy adults using GHRP-2 has never been published. The ACTH/cortisol elevation equivalent to hCRH is a documented, reproducible effect that distinguishes GHRP-2 unfavorably from ipamorelin for most therapeutic applications. The FDA's expected continued Category 2 classification specifically cites these cortisol and prolactin concerns.
For the calculator and research community: GHRP-2 is a well-understood peptide with real GH-releasing activity and meaningful non-selectivity. Ipamorelin produces comparable GH stimulation with dramatically less cortisol and prolactin elevation. The research community's preference for GHRP-2 over ipamorelin is largely historical -- ipamorelin became available later and replaced GHRP-2 in most protocols for users who want selectivity. The case for using GHRP-2 instead of ipamorelin in 2026 would need to articulate a specific benefit from the cortisol or appetite effects, which most users do not want.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use